TY - JOUR
T1 - Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease
AU - Malik, Mobin
AU - Suboc, Tisha M.
AU - Tyagi, Sudhi
AU - Salzman, Nita
AU - Wang, Jingli
AU - Ying, Rong
AU - Tanner, Michael J.
AU - Kakarla, Mamatha
AU - Baker, John E.
AU - Widlansky, Michael E.
N1 - Funding Information:
The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR001436. This work was funded, in part, by a grant from the Clinical Translational Research Initiative of Southeast Wisconsin (UL1TR001436). M.E. Widlansky is supported by HL125409, HL128240, and American Heart Association grant 15SFRN23910002. J.E. Baker is supported by HL054075 and grant NNX15AD69G from the National Aeronautics and Space Administration. N. Salzman is supported by DK088831 and GM122503. M. Malik, T.M. Suboc, and J. Wang received support from T32HL007792. S. Tyagi is supported by T32GM089586.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - Rationale: A strong association has emerged between the gut microbiome and atherosclerotic disease. Our recent data suggest Lactobacillus plantarum 299v (Lp299v) supplementation reduces infarct size in male rats. Limited human data are available on the impact of Lp299v on the vasculature. Objective: To determine whether oral Lp299v supplementation improves vascular endothelial function and reduces systemic in?ammation in humans with stable coronary artery disease (CAD). Methods and Results: Twenty men with stable CAD consumed a drink containing Lp299v (20 billion CFU) once daily for 6 weeks. After a 4-week washout, subjects were given an option of additionally participating in a 10-day study of oral liquid vancomycin (250 mg QID). Vascular endothelial function was measured by brachial artery?ow-mediated dilation. Before and after Lp299v, plasma short-chain fatty acids, trimethylamine oxide, and adipokine levels were measured. Additional plasma samples underwent unbiased metabolomic analyses using liquid chromatography/mass spectroscopy. 16S rRNA sequencing was used to determine changes of the stool microbiome. Arterioles from patients with CAD were obtained, and endothelium-dependent vasodilation was measured by video microscopy after intraluminal incubation with plasma from Lp299v study subjects. Lp299v supplementation improved brachial?ow-mediated dilation (P=0.008) without signifcant changes in plasma cholesterol profles, fasting glucose, or body mass index. Vancomycin did not impact?ow-mediated dilation. Lp299v supplementation decreased circulating levels of IL (interleukin)-8 (P=0.01), IL-12 (P=0.02), and leptin (P=0.0007) but did not signifcantly change plasma trimethylamine oxide concentrations (P=0.27). Plasma propionate (P=0.004) increased, whereas acetate levels decreased (P=0.03). Post-Lp299v plasma improved endothelium-dependent vasodilation in resistance arteries from patients with CAD (P=0.02).16S rRNA analysis showed the Lactobacillus genus was enriched in postprobiotic stool samples without other changes. Conclusions: Lp299v improved vascular endothelial function and decreased systemic in?ammation in men with CAD, independent of changes in traditional risk factors and trimethylamine oxide. Circulating gut-derived metabolites likely account for these improvements and merit further study.
AB - Rationale: A strong association has emerged between the gut microbiome and atherosclerotic disease. Our recent data suggest Lactobacillus plantarum 299v (Lp299v) supplementation reduces infarct size in male rats. Limited human data are available on the impact of Lp299v on the vasculature. Objective: To determine whether oral Lp299v supplementation improves vascular endothelial function and reduces systemic in?ammation in humans with stable coronary artery disease (CAD). Methods and Results: Twenty men with stable CAD consumed a drink containing Lp299v (20 billion CFU) once daily for 6 weeks. After a 4-week washout, subjects were given an option of additionally participating in a 10-day study of oral liquid vancomycin (250 mg QID). Vascular endothelial function was measured by brachial artery?ow-mediated dilation. Before and after Lp299v, plasma short-chain fatty acids, trimethylamine oxide, and adipokine levels were measured. Additional plasma samples underwent unbiased metabolomic analyses using liquid chromatography/mass spectroscopy. 16S rRNA sequencing was used to determine changes of the stool microbiome. Arterioles from patients with CAD were obtained, and endothelium-dependent vasodilation was measured by video microscopy after intraluminal incubation with plasma from Lp299v study subjects. Lp299v supplementation improved brachial?ow-mediated dilation (P=0.008) without signifcant changes in plasma cholesterol profles, fasting glucose, or body mass index. Vancomycin did not impact?ow-mediated dilation. Lp299v supplementation decreased circulating levels of IL (interleukin)-8 (P=0.01), IL-12 (P=0.02), and leptin (P=0.0007) but did not signifcantly change plasma trimethylamine oxide concentrations (P=0.27). Plasma propionate (P=0.004) increased, whereas acetate levels decreased (P=0.03). Post-Lp299v plasma improved endothelium-dependent vasodilation in resistance arteries from patients with CAD (P=0.02).16S rRNA analysis showed the Lactobacillus genus was enriched in postprobiotic stool samples without other changes. Conclusions: Lp299v improved vascular endothelial function and decreased systemic in?ammation in men with CAD, independent of changes in traditional risk factors and trimethylamine oxide. Circulating gut-derived metabolites likely account for these improvements and merit further study.
KW - Coronary artery disease
KW - Endothelium
KW - Gastrointestinal microbiome
KW - Humans
KW - Probiotics
UR - http://www.scopus.com/inward/record.url?scp=85055600525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055600525&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.118.313565
DO - 10.1161/CIRCRESAHA.118.313565
M3 - Article
C2 - 30355158
AN - SCOPUS:85055600525
SN - 0009-7330
VL - 123
SP - 1091
EP - 1102
JO - Circulation Research
JF - Circulation Research
IS - 9
ER -